158 related articles for article (PubMed ID: 36705597)
1. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Jenkins S; Zhang W; Steinberg SM; Nousome D; Houston N; Wu X; Armstrong TS; Burton E; Smart DD; Shah R; Peer CJ; Mozarsky B; Arisa O; Figg WD; Mendoza TR; Vera E; Brastianos P; Carter S; Gilbert MR; Anders CK; Connolly RM; Tweed C; Smith KL; Khan I; Lipkowitz S; Steeg PS; Zimmer AS
Clin Cancer Res; 2023 Apr; 29(8):1450-1459. PubMed ID: 36705597
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
4. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Zimmer AS; Steinberg SM; Smart DD; Gilbert MR; Armstrong TS; Burton E; Houston N; Biassou N; Gril B; Brastianos PK; Carter S; Lyden D; Lipkowitz S; Steeg PS
Future Oncol; 2020 May; 16(14):899-909. PubMed ID: 32270710
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Abraham J; Montero AJ; Jankowitz RC; Salkeni MA; Beumer JH; Kiesel BF; Piette F; Adamson LM; Nagy RJ; Lanman RB; Sperinde J; Huang W; Allegra CJ; Srinivasan A; Wang Y; Pogue-Geile KL; Lucas PC; Jacobs SA
J Clin Oncol; 2019 Oct; 37(29):2601-2609. PubMed ID: 31442103
[TBL] [Abstract][Full Text] [Related]
10. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
Cortés J; Diéras V; Lorenzen S; Montemurro F; Riera-Knorrenschild J; Thuss-Patience P; Allegrini G; De Laurentiis M; Lohrisch C; Oravcová E; Perez-Garcia JM; Ricci F; Sakaeva D; Serpanchy R; Šufliarský J; Vidal M; Irahara N; Wohlfarth C; Aout M; Gelmon K
JAMA Oncol; 2020 Aug; 6(8):1203-1209. PubMed ID: 32584367
[TBL] [Abstract][Full Text] [Related]
14. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.
Stumpf PK; Cittelly DM; Robin TP; Carlson JA; Stuhr KA; Contreras-Zarate MJ; Lai S; Ormond DR; Rusthoven CG; Gaspar LE; Rabinovitch R; Kavanagh BD; Liu A; Diamond JR; Kabos P; Fisher CM
Clin Cancer Res; 2019 Jul; 25(13):3946-3953. PubMed ID: 30940654
[TBL] [Abstract][Full Text] [Related]
15. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
[TBL] [Abstract][Full Text] [Related]
17. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
18. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Cao KI; Lebas N; Gerber S; Levy C; Le Scodan R; Bourgier C; Pierga JY; Gobillion A; Savignoni A; Kirova YM
Ann Oncol; 2015 Jan; 26(1):89-94. PubMed ID: 25355723
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]